Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead 3Q

Revenues up 15% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead

3Q Revenues: $2.8 billion (+15%)

3Q Earnings: $785.2 million (+17%)

YTD Revenues: $8.1 billion (+14%)

YTD Earnings: $2.3 billion (+25%)

Comments: Product sales for the quarter increased 20% in the U.S. and 5% in Europe. Antiviral product sales increased 14% to $2.3 billion driven by strong growth in the new single tablet regimen products, Stribild (+722% to $144 million) and Complera/Eviplera (+112% to $210.7 million). Cardiovascular product sales were up 25% to $250.9 million with Letairis sales up 29% to $135.1 million. Ranexa sales were up 22% to $115.8 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters